<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504123</url>
  </required_header>
  <id_info>
    <org_study_id>202001041</org_study_id>
    <nct_id>NCT04504123</nct_id>
  </id_info>
  <brief_title>MMP-9 Inhibition for Recalcitrant Wet AMD</brief_title>
  <official_title>MMP-9 Inhibition for Recalcitrant Wet Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause&#xD;
      of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF)&#xD;
      intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous&#xD;
      studies show that about 90% of treated patients lose minimal visual function after 2 years of&#xD;
      follow-up. There is still, a subset of 15% patients, incomplete responders, that do not&#xD;
      improve and possibly worsen due to the persistence of sub-retinal fluid (with or without&#xD;
      intra-retinal fluid) with chronic treatment.&#xD;
&#xD;
      The investigators plan to evaluate the effect of oral doxycycline versus placebo on the&#xD;
      anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet&#xD;
      age-related macular degeneration. This subset are incomplete or non-responders to current&#xD;
      anti-VEGF intravitreal therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to conduct a double masked, randomized study to assess the effect of&#xD;
      low dose, oral doxycycline 50 mg once a day versus placebo in patients with wet age-related&#xD;
      macular degeneration who are incomplete responders to anti-VEGF extended treatment regimens.&#xD;
&#xD;
      The study will be conducted over 9 months with every 3 month assessments; 6 months&#xD;
      administration period of doxycycline versus placebo (double masked, randomized) and a 3 month&#xD;
      follow up period. The participant visits will occur during clinic visits for standard-of-care&#xD;
      intravitreal injections (IVI).&#xD;
&#xD;
      Medical information will be acquired from the standard of care optical coherence tomography&#xD;
      (OCT), visual acuity (VA), and IVI administered (number, frequency and type of drug).&#xD;
&#xD;
      Blood plasma and aqueous fluid (anterior chamber tap) samples and study drug tolerability&#xD;
      will be obtained at baseline, 6 months and 9 months. Plasma will be obtained to assay for&#xD;
      inflammatory markers: MMP-9 levels and questionnaires will be obtained on 1) vision quality&#xD;
      of life, and 2) study drug tolerance at Baseline, 6 months and 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Doxycycline Hyclate 50 mg versus placebo capsule</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over encapsulation with opaque purple capsule</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of the persistent retinal fluid on optical coherence tomography (OCT)</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients with retinal fluid-free status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in optical coherence tomography (OCT) central media thickness (CMT)</measure>
    <time_frame>9 months compared to baseline</time_frame>
    <description>mean change in central media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA)</measure>
    <time_frame>6 months and 9 months compared to Baseline</time_frame>
    <description>mean change in logMAR / percentage of patients with a gain or loss of more than 5 ETDRS letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intravitreal injections (IVI) administered</measure>
    <time_frame>6 months and 9 months</time_frame>
    <description>total number of anti-VEGF intravitreal injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory mediators matrix metalloproteinases MMP-9 and MMP-9 activity</measure>
    <time_frame>Baseline, 6 months and 9 months</time_frame>
    <description>anterior eye aqueous fluid and blood plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ocular Adverse Events</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>intra-ocular pressure elevation ( more than 10 mmHg) requiring topical ocular hypertensive medications, endophthalmitis, retinal tear and detachment, uveitis, and thromboembolic events will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Systemic Adverse Events</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Allergy or hypersensitivity drug reactions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Exudative Macular Degeneration</condition>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo (inactive) capsule orally once a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Hyclate</intervention_name>
    <description>Doxycycline Hyclate capsules, USP 50 mg</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Antibiotic - tetracycline compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Wet age-related macular degeneration (wAMD);&#xD;
&#xD;
          -  Solely treated with anti-VEGF IVI for active CNV due to wAMD. However, enrolled&#xD;
             patients can have other retinal pathologies such as diabetic retinopathy or vein&#xD;
             occlusion for which they are not being treated with anti-VEGF IVI;&#xD;
&#xD;
          -  Must have persistent sub-retinal with or without intra-retinal fluid due to active CNV&#xD;
             from wAMD and despite receiving at least three consecutive injections with any&#xD;
             anti-VEGF agent;&#xD;
&#xD;
          -  Must not have encountered previous side effects from tetracycline medications.&#xD;
&#xD;
        Exclusion Criteria - Ocular:&#xD;
&#xD;
          -  History of uveitis (including endophthalmitis) or presence of intraocular&#xD;
             inflammation;&#xD;
&#xD;
          -  Presence of significant epiretinal membrane or macular hole causing distortion of&#xD;
             macular anatomy;&#xD;
&#xD;
          -  Presence of media opacity preventing discerning of fluid on OCT;&#xD;
&#xD;
          -  Any prior ophthalmic surgery (including YAG or retinal laser) within the previous 3&#xD;
             months or anticipated need for any ophthalmic surgery (including cataract extraction)&#xD;
             for 9 months following randomization;&#xD;
&#xD;
          -  History of peribulbar corticosteroid injection to the studied eye or the fellow eye&#xD;
             within the past 6 months;&#xD;
&#xD;
          -  History of intravitreal triamcinolone acetonide injection to the studied eye within&#xD;
             the past 4 months;&#xD;
&#xD;
          -  An ocular condition (other than AMD) is present in the studied eye that, in the&#xD;
             opinion of the investigator, might alter visual acuity during the course of the study&#xD;
             (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease,&#xD;
             neovascular glaucoma, and Irvine-Gass syndrome);&#xD;
&#xD;
          -  CNV due to causes other than wAMD;&#xD;
&#xD;
          -  Inability to follow up at the 6th and 9th months time points after recruitment;&#xD;
&#xD;
          -  Missing two or more consecutive injections during the six months treatment period;&#xD;
&#xD;
          -  Patient requiring imminent need for IVI anti-VEGF medication switch or another&#xD;
             treatment intervention, such as photodynamic therapy, during the 9 months trial&#xD;
             period;&#xD;
&#xD;
          -  Presence of fluid associated with geographic atrophy or disciform scar;&#xD;
&#xD;
          -  Any patient with sub-retinal and/or intra-retinal fluid that is not due to CNV (eg,&#xD;
             overlying areas of geographic atrophy;&#xD;
&#xD;
          -  Any patient actively being actively treated for Irvine-Gass Syndrome.&#xD;
&#xD;
        Exclusion Criteria - Systemic:&#xD;
&#xD;
          -  Patient with and/or who developed an unstable medical status (e.g., glycemic control,&#xD;
             blood pressure, cardiovascular disease, individuals who are unlikely or unable to&#xD;
             complete the 9 months trial period) in the opinion of the investigator;&#xD;
&#xD;
          -  Significant renal disease (defined as a serum creatinine &gt;2.5 mg/dL);&#xD;
&#xD;
          -  Systolic blood pressure &gt;180 mm Hg or diastolic blood pressure &gt;110 mm Hg;&#xD;
&#xD;
          -  History of headaches associated with tetracycline therapy&#xD;
&#xD;
          -  History of pseudotumor cerebri;&#xD;
&#xD;
          -  History of tetracycline therapy within the past 6 months;&#xD;
&#xD;
          -  Pregnancy or patient intending to become pregnant within the 9 months of the trial&#xD;
             period. For women of child-bearing potential, a pregnancy test will be performed;&#xD;
&#xD;
          -  Sexually active women of child-bearing potential not actively practicing birth control&#xD;
             by using a medically accepted device or therapy (i.e., intrauterine device, hormonal&#xD;
             contraceptive, or barrier device) during the study period (at least 24 months). This&#xD;
             is important as doxycycline may interfere with the effectiveness of hormonal&#xD;
             contraceptives. Hence, sexually active women of child-bearing potential who use a&#xD;
             hormonal contraceptive will be required to use a second form of contraception to&#xD;
             safeguard against contraceptive failure while participating in the study;&#xD;
&#xD;
          -  Known allergy/intolerance to doxycycline, tetracyclines, or any ingredient in the&#xD;
             study drug or placebo;&#xD;
&#xD;
          -  Patients receiving phenytoin, barbiturates, carbamazepine, digoxin, or isotretinoin;&#xD;
             patients with gastroparesis; patients with a history of gastrectomy, gastric bypass&#xD;
             surgery, or otherwise deemed achlorhydric should all be excluded due to altered&#xD;
             doxycycline pharmacokinetics and/or bioavailability;&#xD;
&#xD;
          -  Patients taking strontium, acitretin, or tretinoin should excluded due to the&#xD;
             potential for serious interactions with doxycycline;&#xD;
&#xD;
          -  Patients with abnormal ALT or AST at baseline will be referred to their primary care&#xD;
             physician for medical clearance for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliott H Sohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elliott H Sohn, MD</last_name>
    <phone>3193563285</phone>
    <email>elliott-sohn@uiowa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics Department of Ophthalmology &amp; Visual Sciences</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine A Sinkey, BSN, CCRC</last_name>
      <phone>319-353-8723</phone>
      <email>christine-sinkey@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Elliott H Sohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Razek G Coussa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. Review.</citation>
    <PMID>25104651</PMID>
  </reference>
  <reference>
    <citation>Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2.</citation>
    <PMID>6208888</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </reference>
  <reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </reference>
  <reference>
    <citation>Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.</citation>
    <PMID>22555112</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.</citation>
    <PMID>23084240</PMID>
  </reference>
  <reference>
    <citation>Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group. Two-year outcomes of &quot;treat and extend&quot; intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015 Jun;122(6):1212-9. doi: 10.1016/j.ophtha.2015.02.009. Epub 2015 Apr 4.</citation>
    <PMID>25846847</PMID>
  </reference>
  <reference>
    <citation>Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007 Oct;144(4):627-37. Review.</citation>
    <PMID>17893015</PMID>
  </reference>
  <reference>
    <citation>Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013 Nov;97(11):1443-6. doi: 10.1136/bjophthalmol-2013-303513. Epub 2013 Aug 21.</citation>
    <PMID>23966368</PMID>
  </reference>
  <reference>
    <citation>Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, Guymer RH, Hunyor AP, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness! Project Investigators. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2015 Mar;99(3):359-64. doi: 10.1136/bjophthalmol-2014-305514. Epub 2014 Sep 23.</citation>
    <PMID>25249615</PMID>
  </reference>
  <reference>
    <citation>Ersoy L, Ristau T, Kirchhof B, Liakopoulos S. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):889-97. doi: 10.1007/s00417-013-2519-9. Epub 2013 Nov 26.</citation>
    <PMID>24271025</PMID>
  </reference>
  <reference>
    <citation>Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3115-20. doi: 10.1167/iovs.08-1689. Epub 2008 Apr 11.</citation>
    <PMID>18408176</PMID>
  </reference>
  <reference>
    <citation>Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009 Jun;29(6):723-31. doi: 10.1097/IAE.0b013e3181a2c1c3.</citation>
    <PMID>19516114</PMID>
  </reference>
  <reference>
    <citation>Brown DM, Tuomi L, Shapiro H; Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013 Jan;33(1):23-34. doi: 10.1097/IAE.0b013e318263cedf.</citation>
    <PMID>23073338</PMID>
  </reference>
  <reference>
    <citation>van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011 Sep;31(8):1449-69. doi: 10.1097/IAE.0b013e3182278ab4. Review.</citation>
    <PMID>21817960</PMID>
  </reference>
  <reference>
    <citation>Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, Russell SR, Boldt HC, Sohn EH. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology. 2013 Oct;120(10):2029-34. doi: 10.1016/j.ophtha.2013.03.016. Epub 2013 May 25. Erratum in: Ophthalmology. 2013 Dec;120(12):2448. Ophthalmology. 2013 Dec;120(12):2448.</citation>
    <PMID>23714319</PMID>
  </reference>
  <reference>
    <citation>Veritti D, Sarao V, Lanzetta P. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther. 2013 May;29(4):437-41. doi: 10.1089/jop.2012.0173. Epub 2012 Dec 6.</citation>
    <PMID>23215753</PMID>
  </reference>
  <reference>
    <citation>Witkin AJ, Rayess N, Garg SJ, Maguire JI, Storey P, Kaiser RS, Hsu J, Vander JF, Ho AC. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment(). Semin Ophthalmol. 2017;32(3):309-315. doi: 10.3109/08820538.2015.1072222. Epub 2015 Sep 4.</citation>
    <PMID>26337539</PMID>
  </reference>
  <reference>
    <citation>Sridhar J, Hsu J, Shahlaee A, Garg SJ, Spirn MJ, Fineman MS, Vander J. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016 Apr;134(4):437-43. doi: 10.1001/jamaophthalmol.2016.0045.</citation>
    <PMID>26914218</PMID>
  </reference>
  <reference>
    <citation>Mirshahi A, Azimi P, Abdolahi A, Mirshahi R, Abdollahian M. Oral Doxycycline Reduces the Total Number of Intraocular Bevacizumab Injections Needed to Control Neovascular Age-related Macular Degeneration. Med Hypothesis Discov Innov Ophthalmol. 2017 Summer;6(2):23-29.</citation>
    <PMID>29367931</PMID>
  </reference>
  <reference>
    <citation>Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004 Apr;122(4):598-614. Review.</citation>
    <PMID>15078679</PMID>
  </reference>
  <reference>
    <citation>Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003 May-Jun;48(3):257-93. Review.</citation>
    <PMID>12745003</PMID>
  </reference>
  <reference>
    <citation>Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008 Dec;115(12):2199-205. doi: 10.1016/j.ophtha.2008.07.007. Epub 2008 Oct 18.</citation>
    <PMID>18930553</PMID>
  </reference>
  <reference>
    <citation>Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236.</citation>
    <PMID>22157632</PMID>
  </reference>
  <reference>
    <citation>Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2194-200.</citation>
    <PMID>9761302</PMID>
  </reference>
  <reference>
    <citation>Tatar O, Adam A, Shinoda K, Eckert T, Scharioth GB, Klein M, Yoeruek E, Bartz-Schmidt KU, Grisanti S. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br J Ophthalmol. 2007 Sep;91(9):1183-9. Epub 2007 May 2.</citation>
    <PMID>17475706</PMID>
  </reference>
  <reference>
    <citation>Nussenblatt RB, Ferris F 3rd. Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol. 2007 Oct;144(4):618-26. Epub 2007 Aug 15. Review.</citation>
    <PMID>17698021</PMID>
  </reference>
  <reference>
    <citation>Johnson LV, Anderson DH. Age-related macular degeneration and the extracellular matrix. N Engl J Med. 2004 Jul 22;351(4):320-2.</citation>
    <PMID>15269309</PMID>
  </reference>
  <reference>
    <citation>Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005 Jun;40(3):352-68. Review.</citation>
    <PMID>15947805</PMID>
  </reference>
  <reference>
    <citation>Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999 Oct;44 Suppl 1:S10-32.</citation>
    <PMID>10548114</PMID>
  </reference>
  <reference>
    <citation>Chong NH, Keonin J, Luthert PJ, Frennesson CI, Weingeist DM, Wolf RL, Mullins RF, Hageman GS. Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am J Pathol. 2005 Jan;166(1):241-51.</citation>
    <PMID>15632016</PMID>
  </reference>
  <reference>
    <citation>Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002 Mar;2(3):161-74. Review.</citation>
    <PMID>11990853</PMID>
  </reference>
  <reference>
    <citation>Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. Review.</citation>
    <PMID>12209155</PMID>
  </reference>
  <reference>
    <citation>Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998 Oct;10(5):602-8. Review.</citation>
    <PMID>9818170</PMID>
  </reference>
  <reference>
    <citation>Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Danø K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999 Sep 1;18(17):4645-56.</citation>
    <PMID>10469644</PMID>
  </reference>
  <reference>
    <citation>Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der Burg B, Baeuerle PA, van der Saag PT. Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem. 1997 Aug 29;272(35):22278-84.</citation>
    <PMID>9268377</PMID>
  </reference>
  <reference>
    <citation>Kvanta A, Shen WY, Sarman S, Seregard S, Steen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res. 2000 Sep;21(3):684-90.</citation>
    <PMID>11120556</PMID>
  </reference>
  <reference>
    <citation>Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000 Apr;70(4):419-28.</citation>
    <PMID>10865990</PMID>
  </reference>
  <reference>
    <citation>Guo L, Hussain AA, Limb GA, Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2676-82.</citation>
    <PMID>10509665</PMID>
  </reference>
  <reference>
    <citation>Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2367-75.</citation>
    <PMID>10476804</PMID>
  </reference>
  <reference>
    <citation>Fiotti N, Pedio M, Battaglia Parodi M, Altamura N, Uxa L, Guarnieri G, Giansante C, Ravalico G. MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration. Genet Med. 2005 Apr;7(4):272-7.</citation>
    <PMID>15834245</PMID>
  </reference>
  <reference>
    <citation>Oshima Y, Oshima S, Nambu H, Kachi S, Hackett SF, Melia M, Kaleko M, Connelly S, Esumi N, Zack DJ, Campochiaro PA. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol. 2004 Dec;201(3):393-400.</citation>
    <PMID>15389527</PMID>
  </reference>
  <reference>
    <citation>Samtani S, Amaral J, Campos MM, Fariss RN, Becerra SP. Doxycycline-mediated inhibition of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5098-106. doi: 10.1167/iovs.08-3174. Epub 2009 Jun 10.</citation>
    <PMID>19516001</PMID>
  </reference>
  <reference>
    <citation>Roychoudhury J, Herndon JM, Yin J, Apte RS, Ferguson TA. Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3560-6. doi: 10.1167/iovs.09-3890. Epub 2010 Feb 17.</citation>
    <PMID>20164456</PMID>
  </reference>
  <reference>
    <citation>Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001 Mar;158(3):1161-72.</citation>
    <PMID>11238064</PMID>
  </reference>
  <reference>
    <citation>Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1168-75.</citation>
    <PMID>11923262</PMID>
  </reference>
  <reference>
    <citation>Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999 Jul 9;285(5425):245-8.</citation>
    <PMID>10398599</PMID>
  </reference>
  <reference>
    <citation>Becerra SP. Focus on Molecules: Pigment epithelium-derived factor (PEDF). Exp Eye Res. 2006 May;82(5):739-40. Epub 2005 Dec 20. Review.</citation>
    <PMID>16364294</PMID>
  </reference>
  <reference>
    <citation>Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS, Cingolani C, Lai H, Wei L, Campochiaro PA. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 2003 Apr;10(8):637-46.</citation>
    <PMID>12692592</PMID>
  </reference>
  <reference>
    <citation>Lambert V, Munaut C, Jost M, Noël A, Werb Z, Foidart JM, Rakic JM. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol. 2002 Oct;161(4):1247-53.</citation>
    <PMID>12368198</PMID>
  </reference>
  <reference>
    <citation>Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell HW, Foidart JM, Noël A, Rakic JM. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003 Dec;17(15):2290-2. Epub 2003 Oct 16.</citation>
    <PMID>14563686</PMID>
  </reference>
  <reference>
    <citation>Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 Oct;2(10):737-44.</citation>
    <PMID>11025665</PMID>
  </reference>
  <reference>
    <citation>Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4360-7.</citation>
    <PMID>17724228</PMID>
  </reference>
  <reference>
    <citation>Liutkeviciene R, Lesauskaite V, Sinkunaite-Marsalkiene G, Zaliuniene D, Zaliaduonyte-Peksiene D, Mizariene V, Gustiene O, Jasinskas V, Jariene G, Tamosiunas A. The Role of Matrix Metalloproteinases Polymorphisms in Age-Related Macular Degeneration. Ophthalmic Genet. 2015 Jun;36(2):149-55. doi: 10.3109/13816810.2013.838274. Epub 2013 Sep 30.</citation>
    <PMID>24079541</PMID>
  </reference>
  <reference>
    <citation>Chau KY, Sivaprasad S, Patel N, Donaldson TA, Luthert PJ, Chong NV. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye (Lond). 2008 Jun;22(6):855-9.</citation>
    <PMID>18597988</PMID>
  </reference>
  <reference>
    <citation>Jonas JB, Tao Y, Neumaier M, Findeisen P. Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta Ophthalmol. 2012 Aug;90(5):e381-8. doi: 10.1111/j.1755-3768.2012.02414.x. Epub 2012 Apr 10.</citation>
    <PMID>22490043</PMID>
  </reference>
  <reference>
    <citation>Thode AR, Latkany RA. Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). Drugs. 2015 Jul;75(11):1177-85. doi: 10.1007/s40265-015-0432-8. Review.</citation>
    <PMID>26130187</PMID>
  </reference>
  <reference>
    <citation>Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges. 2006 Oct;4(10):828-41. Review. English, German.</citation>
    <PMID>17010172</PMID>
  </reference>
  <reference>
    <citation>Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. 2006 Nov;90(6):1089-107. Review.</citation>
    <PMID>17116438</PMID>
  </reference>
  <reference>
    <citation>Doughty MJ. On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction (MGD). Cont Lens Anterior Eye. 2016 Feb;39(1):2-8. doi: 10.1016/j.clae.2015.08.002. Epub 2015 Sep 4. Review.</citation>
    <PMID>26347083</PMID>
  </reference>
  <reference>
    <citation>Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989 Jul;30(7):1569-75.</citation>
    <PMID>2545645</PMID>
  </reference>
  <reference>
    <citation>Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995 Feb;22(2):100-9.</citation>
    <PMID>7775665</PMID>
  </reference>
  <reference>
    <citation>Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998 Nov;12(2):12-26. Review.</citation>
    <PMID>9972117</PMID>
  </reference>
  <reference>
    <citation>Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann N Y Acad Sci. 1994 Sep 6;732:112-31.</citation>
    <PMID>7978785</PMID>
  </reference>
  <reference>
    <citation>García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL Jr, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol. 2005 Apr;67(4):1128-36. Epub 2005 Jan 21.</citation>
    <PMID>15665254</PMID>
  </reference>
  <reference>
    <citation>Alvarenga LS, Mannis MJ. Ocular rosacea. Ocul Surf. 2005 Jan;3(1):41-58.</citation>
    <PMID>17131004</PMID>
  </reference>
  <reference>
    <citation>Notari L, Miller A, Martínez A, Amaral J, Ju M, Robinson G, Smith LE, Becerra SP. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2736-47.</citation>
    <PMID>16043845</PMID>
  </reference>
  <reference>
    <citation>Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1156-63. doi: 10.1167/iovs.10-6293. Print 2011 Feb. Review.</citation>
    <PMID>21357409</PMID>
  </reference>
  <reference>
    <citation>Scott IU, Jackson GR, Quillen DA, Klein R, Liao J, Gardner TW. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy: a randomized proof-of-concept clinical trial. JAMA Ophthalmol. 2014 Sep;132(9):1137-42. doi: 10.1001/jamaophthalmol.2014.1422.</citation>
    <PMID>24969516</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Elliott Sohn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Active choroidal neovascularization (CNV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators do not plan to share the data with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

